3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Infections -

Electrically charged acyclovir speeds herpes healing

InfectionsAug 18, 06

A device that uses “iontophoresis” to enhance tissue penetration of topically applied acyclovir speeds the healing of cold sores, a study shows.

Iontophoresis refers to the use of a small electric current to move ionized substances through the skin into tissues.

“The results of this study are very exciting because of the timing of treatment,” Dr. Dennis I. Goldberg from Transport Pharmaceuticals, Framingham, Massachusetts told Reuters Health.

“Since patients were required to set up an appointment and then come into the clinic, treatment was delayed for up to 24 hours after first signs and symptoms. In spite of that, the results were extremely encouraging,” Goldberg explained.

The Iontophoretic Acyclovir Cold Sore Study Group tested Transport Pharmaceutical’s new handheld iontophoretic device in a clinical study to determine whether improved transdermal delivery of acyclovir translates into better efficacy in treating cold sores caused by herpes.

The pen-sized device generates a low-voltage weak electric current. It holds an acyclovir reservoir on its head electrode, which is then applied to the cold sore as the patient holds hydrogel electrodes on the device to complete the circuit.

The study involved 200 patients experiencing a herpes outbreak who were randomly assigned to use the device with either acyclovir cream or placebo cream.

A single 10-minute treatment was associated with an increased frequency of aborted lesions (46 percent versus 24 percent in the placebo group), the authors report, but this difference was apparent only in subjects who received treatment when only redness was present.

The frequency of aborted lesions did not differ among patients who already had a lesion or edema (swelling).

The median time to healing was shortened by 71 hours in the group treated at the redness stage and by 35 hours in the group treated at the lesion/edema stage, and the latter difference was not statistically significant.

Among the 17 side effects in the active treatment group and the 19 side effects in the placebo treatment group, the most common was a mild electrical sensation that required no treatment, the researchers note.

SOURCE: Clinical Infectious Diseases August 15, 2006.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  Many European countries ill-prepared to prevent and control the spread of viral hepatitis
  HPV vaccination not associated with increase in sexually transmitted infections
  Hepatitis C more prevalent than HIV/AIDS or Ebola yet lacks equal attention
  To curb hepatitis C, test and treat inmates
  Vinegar kills tuberculosis and other mycobacteria
  New strategy emerges for fighting drug-resistant malaria
  Toys, books, cribs harbor bacteria for long periods, study finds
  California high school to test students for tuberculosis
  TB Vaccine May Work Against Multiple Sclerosis
  Tuberculosis: Nature has a double-duty antibiotic up her sleeve
  Treatment target identified for a public health risk parasite
  Nearly half of U.S. children late receiving vaccines

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site